《2023年全球医疗健康行业私募股权报告》-104页_1mb

Global Healthcare Private Equity and M&A 2023 Report Summary

Annual Overview (2022)
Healthcare private equity (HCPE) demonstrated resilience in 2022, with the year being the second-best on record by deal value, reaching approximately $90 billion. Despite a significant slowdown from 2021 ($151 billion), deal volume remained steady at around 350 transactions. Macroeconomic challenges, including inflation, high interest rates, geopolitical tensions (e.g., Russia-Ukraine war), and labor shortages, pressured the market. Key trends included a shift toward pockets of opportunity in life sciences and healthcare IT (HCIT), with deal activity peaking in the first half and declining in the second quarter due to credit market tightening and reduced deal sizes. Exits saw strong performance, with over 40 deals valued over $500 million, driven by strategic and sponsor-to-sponsor transactions, though public market exits decreased due to depressed valuations.

Challenges in 2022
The macroeconomic environment posed significant hurdles, with inflation (e.g., healthcare wage inflation around 5% in the U.S.) and credit market constraints limiting large transactions. Provider businesses were particularly affected by labor shortages and wage pressures, reducing deal volumes in this sector. Corporate M&A activity declined as companies paused acquisitions amid regulatory scrutiny and financing uncertainty, though strategic buyers remained active in certain assets.

Strategic Responses
PE firms adapted by focusing on recession-resilient themes, such as biopharma services and HCIT, which support operational efficiency. Creative deal strategies emerged, including public-to-private acquisitions (e.g., Covetrus deal for $4 billion), carve-outs (e.g., Advarra from Genstar), and minority recapitalizations. Deal volume decreased in the second half, but this allowed firms to concentrate on high-conviction assets and optimize financing through methods like all-equity deals and club financing.

Sector Highlights

• Life Sciences: Deal activity surged, with record value driven by pharma services and tools, offsetting slowdowns in biopharma and diagnostics.
• Providers: Focus narrowed to specialties like dermatology, cardiology, and value-based care, with provider IT accounting for 70% of HCIT deals but declining sector share.
• Payers and Medtech: Payer buyouts slowed, with interest shifting to services and technology; medtech rebounded, with deals concentrating on differentiated OEMs and aesthetic devices.
• Healthcare IT: Provider IT led HCIT activity, but biopharma and payer IT gained attention for administrative and clinical trial support.

Geographical Insights

• North America: Strong start with high deal values, but volumes weakened in the second half due to macro pressures.
• Europe: Deal activity steady, with biopharma and related services leading; however, the second half saw reduced activity amid credit constraints.
• Asia-Pacific: Notable growth outside China, driven by India and Southeast Asia; China's slowdown affected regional deal flow due to policy uncertainties.

Outlook for 2023
The HCPE market faces continued uncertainty, including potential recessions and evolving AI impacts, but long-term healthcare growth trends support resilience. Key areas of opportunity include value-based care expansion, technological advancements (e.g., generative AI in drug discovery), and strategic exits. Silver linings include maturing Asian markets and record dry powder, which may drive recovery in credit-constrained environments. Investors are expected to refine deal strategies, with a focus on operational efficiency and specialized expertise.